We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions.
- Authors
Yan, Zhi-Ling; Wang, Yue-Wen; Chang, Ying-Jun
- Abstract
Multiple myeloma (MM) remains incurable due to relapse, although the use of proteasome inhibitors, immunomodulatory drugs, CD38-targeting antibodies, and autologous stem cell transplantation (auto-SCT) significantly improve the clinical outcomes of patients with newly diagnosed MM. In recent years, the introduction of chimeric antigen receptor T-cell (CAR T-cell) therapy has brought hope to patients with refractory and relapsed MM. The graft-versus-myeloma effect of allogeneic SCT provides the possibility for curing a subset of MM patients. In this review, we summarize the recent advances and challenges of cellular immunotherapies for MM, focusing on auto-SCT, allogeneic SCT, and CAR T-cell approaches. We also discuss future directions, and propose a specific algorithm for cellular therapies for MM and probability of minimal residual disease-directed therapy.
- Subjects
MULTIPLE myeloma treatment; BONE marrow transplantation; CARCINOGENESIS; DISEASE relapse; HEMATOPOIETIC stem cell transplantation; T cells; SALVAGE therapy; IMMUNOTHERAPY; ALGORITHMS; PROBABILITY theory
- Publication
Oncology & Therapy, 2022, Vol 10, Issue 1, p85
- ISSN
2366-1070
- Publication type
Article
- DOI
10.1007/s40487-022-00186-4